首页> 外文OA文献 >Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications
【2h】

Regulatory Affairs 101: Introduction to Investigational New Drug Applications and Clinical Trial Applications

机译:监管事务101:调查新药应用和临床试验应用介绍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Testing novel drugs on fellow human beings is fraught with potential ethical concerns; however, developing drugs to treat the wide spectrum of human diseases and disorders is a moral imperative. How do we best navigate the balance between protecting the individual vs. the greater good? Global government regulatory bodies are accountable for ensuring that medical experiments on human subjects are appropriately justified and subject to close oversight. In this article, we focus on two major global health authorities, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and the path to legally treating humans with new investigational products.
机译:在人类的人物上测试新药被潜在的道德问题造成潜在的道德问题;然而,发展药物以治疗广泛的人类疾病和疾病是一种道德势在必行。我们如何最好地导航保护个人与保护之间的平衡。全球政府监管机构负责确保对人类受试者的医学实验进行适当的合理,并受到近似监督。在本文中,我们专注于两个主要的全球卫生当局,美国食品和药物管理局(FDA)和欧洲药物局(EMA),以及法律处理新的调查产品的道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号